TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 16:48 · AI Infrastructure · Enterprise AI shifting to cost-per-task, tiered models, token maxing
episode briefing
20VC

Meta Takes on OpenAI | Apple Sues OpenAI | SK Hynix’s $26BN IPO

2026-07-16 · 7 company · 6 thematic
sentiment
0 bull3 bear4 neu
speakers
rory o'driscoll

Rory O'Driscoll is a partner at Scale Venture Partners, a late-stage venture firm. He references Scale's portfolio (Linear, DataBricks, HubSpot, Salesforce, Palantir) and fund dynamics. He previously invested in Anthropic (2021) and tracks AI infrastructure closely.

jason lemkin

Founder of SaaStr, a community and media platform for B2B software founders and executives. He is an early-stage investor and a frequent commentator on SaaS growth and go-to-market strategy.

now playing · AI Infrastructure
AI Infrastructuretailwindscore 9/10rory o'driscoll
Enterprise AI shifting to cost-per-task, tiered models, token maxing
CIOs moving from cost-per-token to cost-per-completed-task; every company will need tiered model strategy (frontier for complex, cheap for volume); developer token consumption exploding as…
AI Economics & Business Modelsriskscore 9/10rory o'driscoll
Foundation models approaching hard TAM ceiling in software spend
OpenAI/Anthropic revenue growing at unprecedented rates but US software engineering spend only $250B total; already capturing ~20% — next 12 months will test if growth decelerates or CFOs r…
Memory & Storageheadwindscore 8/10rory o'driscoll
Memory oligopoly at peak cyclical margins, correction inevitable
Three memory companies (SK Hynix, Samsung, Micron) are peak beneficiaries of AI capex, trading at 5-8x P/E with 70% net margins, but historical cyclicality suggests inevitable correction wh…
Venture Capitaltailwindscore 8/10rory o'driscoll
Late-stage growth funds replacing public markets, secondaries highly liquid
New asset class of late-stage private funds (Altimeter, Thrive) replacing public markets for high-growth companies; secondary markets now highly liquid enabling early exits; fund size disci…
AI Drug Discoverymixedscore 7/10rory o'driscoll
AI drug discovery business model uncertain: platform vs biotech economics
AI drug discovery companies (Isomorphic, Chai, Latent Labs) attracting massive capital but unclear if they follow platform/LLM economics (winner-take-most) or traditional biotech economics…
Enterprise Softwareheadwindscore 9/10jason lemkin
Pre-AI SaaS facing accelerating terminal decay from AI-native alternatives
Legacy SaaS (Marketo, etc.) seeing renewal cycles collapse from years to days due to AI-native switching; Constellation's 3x revenue rollup bets on 10+ year cash flows that may not material…